Figure 4.
Molecular docking models of α-glucosidase inhibition at catalytic (a–f) and allosteric sites (g–l) by compounds 1–3 and 5–7, respectively: (a,g) for kuwanon C (1); (b,h) for moracin M (2); (c,i) for dihydromorin (3); (d,j) for oxyresveratrol (5); (e,k) for norartocarpetin (6); (f,l) for kuwanon G (7).
